Thursday, August 23, 2018
AngioDynamics to Present at Two Investor Conferences in September
LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 23, 2018-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that it will present at the following two investor conferences in...

  Wednesday, August 15, 2018
AngioDynamics Provides Updates on Oncology and Vascular Access Businesses
LATHAM, N.Y. --(BUSINESS WIRE)--Aug. 15, 2018-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and...

  Wednesday, July 11, 2018
AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results
Fiscal 2018 Fourth Quarter Highlights Net sales of $88.3 million , an increase of 1.6% year over year Gross margin expanded 500 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.20 per share Operating cash flow of $23.8 million ; free cash flow of $23.0 million...

  Thursday, June 21, 2018
AngioDynamics to Report Fiscal 2018 Fourth Quarter and Full-Year Financial Results on July 11, 2018
LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 21, 2018-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the fourth...

  Wednesday, April 11, 2018
AngioDynamics to Present at Two Investor Conferences in May
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will present at the following two investor conferences in May:...

  Monday, April 9, 2018
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
Fiscal 2018 Third Quarter Highlights Net sales of $83.9 million , a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37 ; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough...

  Monday, April 9, 2018
AngioDynamics to Present at the Needham 17th Annual Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial...

  Monday, April 9, 2018
AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal...

  Monday, April 9, 2018
AngioDynamics to Present at the Barclays Global Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and Michael C....

  Wednesday, February 7, 2018
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted...

  Wednesday, February 7, 2018
AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results
Fiscal 2018 Second Quarter Highlights Net sales of $86.7 million , a decrease of 2.6% year over year U.S. GAAP EPS of $0.01 ; Adjusted EPS of $0.16 per share Operating cash flow of $10.2 million ; free cash flow of $9.4 million LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a...

  Tuesday, December 19, 2017
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2017-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer , President and Chief Executive Officer,...

  Monday, December 11, 2017
AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 11, 2017-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second...

  Saturday, October 7, 2017
AngioDynamics Reports Fiscal 2018 First Quarter Results
Q1 net sales of $85.4 million , down 3% year-over-year              Q1 GAAP earnings per share of $0.00 ; adjusted EPS of $0.12 Q1 operating cash generation of $3.0 million ; free cash flow generation of $2.5 million Company reaffirms fiscal 2018 guidance ALBANY, N.Y. , Sept....

  Saturday, October 7, 2017
Outcomes in a Nurse-Led Peripherally Inserted Central Catheter Program: A Retrospective Cohort Study Published in CMAJ Open
Low rates of major PICC-associated complications attributed in-part to the novel BioFlo catheter material Data to be presented at AngioDynamics -sponsored symposium at the annual scientific meeting of the Association for Vascular Access ALBANY, N.Y. , Sept....